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Abstract
The geographical distribution of hepatitis B virus (HBV) subgenotypes and their clinical implications in patients with acute and chronic
hepatitis B in the Heilung-kiang province of northeast China were investigated. Nested PCR and multiplex PCR were performed with
genotype-specific primers and with subgenotype-specific primers to identify genotypes and subgenotypes from serum samples of 412
HBV infections including 69 with acute self-limited hepatitis (ASH) and 343 with chronic hepatitis (CH). A total of 361 samples were
genotyped and 304 were further subgenotyped. The most common HBV genotype was C (93.63%, 338/361), with subgenotype group
C2 (83.73%, 283/338) predominating. Genotype B was also found and subgenotype B2 predominated within this genotype. Out of 69
infected patients with ASH, 48 were identified as genotype C and all belonged to subgenotype C2. Of 343 infected patients with CH,
313 were genotyped and 256 were subgenotyped; amongst these, C2 (91.80%, 235/256), B2 (7.42%, 19/256) and mixed subgenotypes
B2 and C2 (0.78%, 2/256) were found. In HBV subgenotype C2 infections, ASH had a higher ratio of women than CH patients. These
results show that HBV subgenotypes C2 and B2 were found in Heilung-kiang province of northeast China. In ASH and CH groups, the
distributions of subgenotypes were coincident with C2, the predominant subgenotype. Analysis of the association between subgenotype
and the outcomes of HBV infection was inconclusive in our study.
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Introduction
Hepatitis B virus (HBV) infection is associated with a wide vari-
ety of clinical outcomes, including acute hepatitis (AH), asymp-
tomatic carrier status, and chronic hepatitis (CH). Many adult
patients with acute hepatitis B have naturally self-limiting infec-
tions [1]. Some chronically infected individuals develop cirrho-
sis or hepatocellular carcinoma. There are currently an
estimated 400 million chronic HBV infections worldwide [2].
HBV infection in China is currently prevalent at 10–20% [3].
HBV is classified into at least eight genotypes (A–H), based
on nucleotide sequence divergence among strains of >8%
[4–7]. HBV genotypes can be further divided into
subgenotypes based on a >4% diversity in the complete
nucleotide sequence. These subgenotypes may vary in geo-
graphical distribution, viral characteristics, and relationship to
clinical outcomes [8,9]. In Asia, HBV genotype B and C are
highly prevalent. Genotype B includes seven geographically
segregated subgenotypes [10,11]. Subgenotype B1 circulates in
Japan, B2 in Asia, B3 in Indonesia, B4 and B5 in Vietnam, and
recently B6 and B7 were found in Arctic indigenous popula-
tions and in the Nusa Tenggara islands in eastern Indonesia.
The six subgenotypes of genotype C are also geographically
segregated [12–15]. The subgenotype C1 circulates in South-
east Asia and Southern China, C2 in East Asia, C3 in Oceania,
C4 appears predominantly in Australian Aboriginals, C5 circu-
lates in Vietnam and the Philippines and recently C6 has been
found in Indonesia. In China, the largest country in Asia, the
most common HBV genotypes are B and C. The distributions
of HBV genotypes differ greatly in different regions in China,
with a North–South divide in the prevalence of genotype
C and B, respectively. In the northern regions of China geno-
type C is predominant and genotype B is more frequently
found in southern China. In some regions of northern China,
subgenotype C2 is predominant, whereas subgenotype C1 is
more prevalent than C2 in southern China [16–18].
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There are no current studies describing subgenotype dis-
tributions in northeast China and very few studies describe
the clinical outcomes of acute HBV infection based on geno-
type or subgenotype worldwide. This study investigated HBV
subgenotype distribution and clinical implications in acute
and chronic HBV patients in the Heilung-kiang province of
northeast China.
Materials and Methods
Patients
A total of 412 samples from patients infected with HBV (309
male and 103 female, mean age 38.8 ± 11.7 years) were col-
lected from the following five hospitals of Heilung-kiang
Province: Harbin Infectious Diseases Hospital (n = 32); The
Chinese People’s Liberation Army 211th hospital (n = 1) and
the First, Second and Fourth Affiliated Hospitals, Harbin
Medical University (n = 2, n = 376 and n = 1, respectively)
from November 2006 to April 2008. All patients in our
study demonstrated hepatitis B surface antigen (HBsAg),
HBV DNA (‡1.0 · 102 copies/mL) and the absence of anti-
bodies against hepatitis A, hepatitis C, hepatitis D, and
human immunodeficiency viruses (HIV). Patients were subdi-
vided into the two groups: acute self-limited hepatitis (ASH)
and CH. The demographics and detailed descriptions of the
serology can be seen in Table 1. Individuals in the ASH
group demonstrated high-titre IgM against the HBV core
antigen, and had all recovered from their liver disease, had
lost HBsAg, and most had scored positive for antibodies to
HBsAg during ‡24 weeks after their initial presentation.
Individuals in the CH group, who were hospitalized or
were being seen in the clinical service at the Infectious Dis-
ease Department of the Second Affiliated Hospital of Harbin
Medical University, had shown persistent HBsAg for
>6 months. The study protocol conformed to the 1975 Dec-
laration of Helsinki regulations. The procedures were
approved by our ethics committee and informed, written
consent was obtained from each participant.
Laboratory assays
HBV serology and antibodies against hepatitis A, hepatitis C,
hepatitis D and HIV were determined by ELISA using com-
mercial test kits (Kehua Co., Shanghai, China). Aspartate
aminotransferase (AST) and alanine aminotransferase (ALT)
levels were measured in a clinical laboratory (Modular P800;
Roche, Basel, Switzerland) with commercial test kits (Olym-
pus Diagnostica GmbH; Lismeehan, O’Callaghans’s Mills,
County Clare, Ireland). Serum HBV DNA was quantified by
real-time fluorimetry PCR (GmbH LightCycler1.5; Roche
Diagnostics, Mannheim, Germany) using the Quantitative
Hepatitis B Virus PCR Fluorogence Diagnostic Kit (PG Bio-
technology, Shenzhen, China).
HBV genotyping and subgenotyping
Serum HBV DNA was extracted with a commercial kit
(TIANamp, Beijing, China) according to the manufacturer’s
instructions, suspended in 30 lL distilled water and 2 lL was
used as template for HBV DNA amplification. First, nested
PCR (Bioer XP Cycler; Bioer, Hangzhou, China) was per-
formed using HBV A–F genotype-specific primer pairs [19].
For the samples that were successfully genotyped, the HBV
subgenotypes were further determined by multiplex PCR
with HBV subgenotype-specific primers (for subgenotype C1,
C2, B1 and B2) as described by Chen et al. [20]. Taq DNA
polymerase and the primers were purchased from MBI Fer-
mentas (Glen Burnie, MD, USA) and Genecore Biological
Technology Limited Company (Shanghai, China), respectively.
The thermocycler was changed to an initial denaturation step
of 5 min at 94C, followed by 30 cycles of 94C for 60 s,
48C for 60 s, and 68C for 60 s. The final elongation step
was 72C for 8 min. Amplified PCR products were electro-
phoresed on a 2% agarose gel, stained with ethidium bro-
mide, and analysed by the Gel image system (GIS2010;
Tanon, Shanghai, China).
Statistical analysis
The v2 and t-tests were used for statistical analysis, and
statistical significance was assigned at p values <0.05.
Results
Distribution of HBV subgenotypes in Heilung-kiang province
A total of 87.6% (361/412) samples were successfully
genotyped and 84.2% (304/361) of those samples were
TABLE 1. The demographic and serological description of
HBV infections with ASH and CH
Characteristics
ASH
(n = 69)
CH
(n = 343)
Age (mean ± SD, years) 38.5 ± 12.3 38.8 ± 11.6
Sex (male:female) 2:1 (46:23) 3.2:1 (263:80)
ALT level (mean U)l ± SD) 1528.8 ± 1219.6 209.6 ± 382.7
AST level (mean U)l ± SD) 923.4 ± 696.2 127.0 ± 237.5
HBV DNA (mean ± SD,
copies/mL)
1.2 · 106 ± 5.7 · 106 4.7 · 107 ± 1.3 · 108
Positive for HBeAg 23 (33.3%) 265 (77.3%)
Positive for HBeAb 40 (58.0%) 36 (10.5%)
Positive scores for HBeAg and HBeAb are given as the number of patients (%).
HBV, hepatitis B virus; ASH, acute self-limited hepatitis; CH, chronic hepatitis;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg,
hepatitis B e antigen; HBeAb, antibody to hepatitis B e antigen.
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subgenotyped. The distributions of HBV genotypes were as
follows: C, 93.6% (338/361); B, 5.8% (21/361) and mixed geno-
types B and C, 0.6% (2/361). No other genotypes (A, or D–F)
were found in our study. The distributions of HBV subgeno-
types were as follows: C2, 93.1% (283/304); B2, 6.3% (19/304)
and mixed subgenotypes B2 and C2, 0.7% (2/304). Subgeno-
types C1 and B1 were not found in our study. PCR reactions
in which no amplification product was obtained accounted for
12.4% (51/412) of the genotype and 15.8% (57/361) of the
subgenotype determinations. The results suggest that sub-
genotype C2 is predominant in Heilung-kiang province.
Distribution of HBV subgenotypes in ASH and CH groups
All 412 patients were subdivided into the two groups, ASH
(n = 69) and CH (n = 343). In the ASH group, 69.6% (48/69)
of samples were successfully genotyped; C accounted for
100% (48/48) and all belonged to subgenotype C2. In the
CH group, 91.3% (313/343) of samples were successfully
genotyped, and the genotypes found at the following fre-
quencies: C, 92.7% (290/313); B, 6.7% (21/313) and mixed
genotypes B and C, 0.64% (2/313). A total of 81.79% (256/
313) of the samples were successfully subgenotyped, in
which the frequencies of the different subgenotypes were
C2, 91.8% (235/256); B2, 7.4% (19/256); and mixed subgeno-
types B2 and C2, 0.8% (2/256). The distribution of subgeno-
type C2 in ASH and CH groups was not significantly
different statistically (v2 = 2.7, p 0.10). These results suggest
that the distributions of HBV subgenotypes were coincident
in ASH and CH patients and show that the subgenotype C2
was predominant in the two groups.
Comparison between ASH and CH patients infected with
subgenotype C2
The demographic and clinical data on subgenotype C2 infec-
tions in ASH and CH groups are shown in Table 2. When
compared with CH patients, ASH patients had a higher ratio
of women (ASH male:female, 31:17 vs. CH, 185:50, p 0.02),
higher HBeAb (antibody to hepatitis B e antigen) positive
rate (35.4% vs. 9.8%, p <0.001), higher serum ALT and AST
levels (1524.7 ± 848.1 ul vs. 182.5 ± 304.1 ul, p <0.001;
990.8 ± 675.5 ul vs. 107.6 ± 146.2 ul, p <0.001, respectively),
lower HBeAg (hepatitis B e antigen) positive rates (31.2% vs.
77.9%, p <0.001) and lower serum HBV DNA levels
(1.7 · 106 ± 6.9 · 106 vs. 4.4 · 107 ± 1.3 · 108, p <0.001).
Comparison between subgenotype C2 and B2 infections in
the CH group
The demographic and clinical data from subgenotype C2
and B2 infections are shown in Table 3. No significant dif-
ferences were observed between subgenotype B2 and C2
infections when age, HBeAg positive rate, HBeAb positive
rate, serum HBV DNA, ALT or AST levels were com-
pared (p >0.05). Mixed subgenotypes B2 and C2 were
identified in two CH infections and these data were
TABLE 2. Comparison between
ASH and CH patients infected with
subgenotype C2
Characteristics ASH (n = 48) CH (n = 235) p-value
Age (mean ± SD, years) 39.7 ± 12.2 38.2 ± 10.6 0.37
Sex (male:female) 1.8:1 (31:17) 3.7:1 (185:50) 0.02
ALT level (mean U)l ± SD) 1524.7 ± 848.1 182.5 ± 304.1 0.00
AST level (mean U)l ± SD) 990.8 ± 675.5 107.6 ± 146.2 0.00
HBV DNA (mean ± SD, copies/mL) 1.7 · 106 ± 6.9 · 106 4.4 · 107 ± 1.3 · 108 0.00
Positive for HBeAg 15 (31.2%) 183 (77.9%) 0.00
Positive for HBeAb 17 (35.4%) 23 (9.8%) 0.00
Chi-square test was used when comparing sex ratios HBeAg and HBeAb positive rates; t-tests were used for age,
ALT, AST and HBV DNA levels.
ASH, acute self-limited hepatitis; CH, chronic hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransfer-
ase; HBeAg, hepatitis B e antigen; HBeAb, antibody to hepatitis B e antigen.
TABLE 3. Comparison between
subgenotype C2 and B2 infections
in the CH group
Characteristics CH (n = 235) B2 (n = 19) p-value
Age (mean ± SD, years) 38.2 ± 10.6 36.4 ± 16.5 0.69
Sex (male:female) 3.7:1 (185:50) 2.2:1 13:6 0.45
ALT level (mean U)l ± SD) 182.5 ± 304.1 673.7 ± 1145.2 0.30
AST level (mean U)l ± SD) 107.6 ± 146.2 494.9 ± 884.3 0.29
HBV DNA ( mean ± SD, copies/mL) 4.4 · 107 ± 1.3 · 108 1.1 · 108 ± 2.7 · 108 0.36
Positive for HBeAg 183 (77.9%) 14 (73.7%) 0.96
Positive for HBeAb 23 ( 9.8%) 3 (15.8%) 0.66
CH, chronic hepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBeAg, hepatitis B e antigen;
HBeAb, antibody to hepatitis B e antigen.
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excluded from further analysis because of insufficient num-
bers of patients.
Discussion
In China, the distributions of HBV genotypes in the CH
group have been investigated in many regions [16,18,21,22].
These results suggest that genotype C predominates in
northern China, genotype B predominates in southern China,
genotype D is prevalent in Xinjiang, genotype A is rare, and
genotypes E, F, G and H are not found. Up to now, the dis-
tribution of HBV genotypes in ASH groups has not been
reported in China. We analysed a cohort of 69 patients with
ASH, and found that genotype C was the most prevalent;
the same was true of the distribution of genotypes in CH
group in this region. For the distribution of subgenotypes,
Wang et al. [17,23] and Li et al. [18] reported that in CH
patients infected with genotype C, the majority were of
subgenotype C2 in northern and southeastern China. By
contrast, subgenotype C1 was more prevalent in southern
China.
Within genotype B, subgenotype B2 was more prevalent
than B1. No other subgenotypes were detected in these
studies. Heilung-kiang province is located further north than
Changchun, and the distribution of HBV subgenotypes in that
province has not been reported before. We investigated the
distribution of subgenotypes in 412 HBV infections including
69 with ASH and 343 with CH, subgenotypes C2, B2 and
mixed subgenotypes C2 and B2 were found and C2 was the
most common in both ASH (100%) and CH (91.8%) groups.
Many studies from Asia have reported that genotype C
takes a more aggressive disease course than genotype B [23–
25]. Genotype B was more prevalent in patients with ASH
[26,27], suggesting that genotype B was associated with a
lower rate of CH infections. Another study, from Japan, indi-
cated that the less common subgenotypes (A2, C1, B2) were
detected more frequently in acute HBV infections [28], and
that persistence of HBV after acute infection was rare and
occurred more often in patients infected with subgenotype
A than others [29].
In our study, the distribution of genotype B/B2 was obvi-
ously lower than C/C2 in the CH group, but in the ASH
group, only genotype C/C2 was detected; the distribution of
(sub) genotypes in ASH and CH groups was consistent. For
this reason, the investigation into the association between
(sub) genotype and the outcomes of HBV infection was
inconclusive in our study. As to why the same subgenotype
C2 is associated with two completely different clinical
outcomes in our study, we have considered several possible
factors. First, there may be some differences present in the
full HBV genomic sequences in subgenotype C2, not
detected by the subgenotyping protocol; sequence differ-
ences have been described in a previous report [30] suggest-
ing that basal core promoter and precore mutations are
associated with progression to fulminant hepatitis in acute
hepatitis B patients infected with subgenotype C2. Second,
perhaps host factors should be evaluated together with sub-
genotype when assessing the outcomes of HBV infection.
For example, the Human Leukocyte Antigen, HLA- DRB1*13
allele [31,32] has been reported to be associated with ASH
or spontaneous viral clearance after HBV infection, whereas
the DRB1*12 allele [33,34] might be correlated with viral
persistence. Third, the higher female ratio in the ASH group
in our study may also contribute to the different outcomes
of HBV subgenotype C2 infections.
Our results also highlight the different clinical features
between ASH and CH patients infected with subgenotype
C2. The different disease process of HBV infections during
enrolment may have contributed to these results. Most CH
patients included in this study were rarely hospitalized with
light clinical symptoms. Conversely, most ASH patients were
hospitalized with intense clinical symptoms and achieved
peak serum ALT and AST levels.
In conclusion, we describe the distribution and clinical
implications of HBV subgenotypes in ASH and CH patients
in the Heilung-kiang province of northeast China. Our results
reveal that subgenotypes C2 and B2 were found in Heilung-
kiang province of northeast China. In ASH and CH groups,
the distributions of subgenotypes were coincident and C2
was predominant. The association between subgenotypes
and the outcomes of HBV infection was inconclusive in our
study.
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